Immunovant, Inc.
IMVT Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$28.88
KIRA · Stoqly’s AI analyst, in plain words
- Immunovant, Inc. lost $506M in fiscal 2026.
- Free cash flow was −$407M in fiscal 2026, — of revenue.
Market cap
$5.9B
P/E
—
Revenue
—
Net income
−$506M
Free cash flow
−$407M
Operating margin
—
Immunovant, Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−$506M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Immunovant, Inc. does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · May 20, 2026
- Legal name
- Immunovant, Inc.
- CIK
- 0001764013
Immunovant, Inc. · IMVT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $7.6M | $24.9M | — | — |
| Revenue growth | — | — | 229.2% | — | — |
| Net interest income | $0.0M | $7.6M | $24.9M | — | — |
| Net income | −$157M | −$211M | −$259M | −$414M | −$506M |
| Net margin | — | −2,783.8% | −1,039.5% | — | — |
| Diluted EPS | −$1.43 | −$1.71 | −$1.88 | −$2.73 | −$2.77 |
| Cash | |||||
| Cash from operations | −$106M | −$188M | −$214M | −$376M | −$407M |
| Capital expenditure | $0.3M | $0.2M | $0.4M | $0.8M | $0.0M |
| Free cash flow | −$106M | −$188M | −$215M | −$377M | −$407M |
| FCF margin | — | −2,486.0% | −860.1% | — | — |
| Share count change | 25.0% | 12.2% | 12.2% | 9.8% | 20.4% |
| Debt and strength | |||||
| Cash and short-term investments | $494M | $377M | $635M | $714M | $902M |
| Shareholders' equity | $470M | $362M | $618M | $707M | $853M |
| Current ratio | 11.5x | 9.3x | 13.7x | 11.2x | 9.1x |
| Returns and quality | |||||
| Return on equity | −36.4% | −50.7% | −52.9% | −62.5% | −64.8% |
| Return on tangible equity | −33.4% | −58.2% | −42.0% | −58.5% | −59.3% |
| Piotroski F-score | — | 2 | 4 | — | — |
Insiders bought, 12 months
$350M
1 insider
Insiders sold, 12 months
$16.3M
9 insiders
Of sales under plans
8%
$1.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Immunovant, Inc. · IMVT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $28.88 a share, the company is worth $5.9B.
Source: SEC EDGAR XBRL filings (CIK 0001764013). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.